Search results for "BREAST"

showing 10 items of 1871 documents

Gimema Registry of Conception/Pregnancy in Adult Patients Diagnosed with Chronic Myeloid Leukemia (CML) Treated with Tyrosine Kinase Inhibitors (TKIs)

2014

Abstract The management of patients with chronic myeloid leukemia (CML) during pregnancy is a matter of continuous debate. The introduction of the tyrosin kinase inhibitors (TKIs) in clinical practice has dramatically changed the prognosis of CML patients. Patients diagnosed in chronic phase can expect an excellent disease control and a normal lifespan. Issues relating to fertility and pregnancy must be introduced at diagnosis. Different reports were published in patients conceving/getting pregnant during Imatinib treatment, while there are only sporadic data about other TKIs. The GIMEMA CML working party has started a retrospective and prospective study to describe all female pregnancies/m…

Gynecologyeducation.field_of_studymedicine.medical_specialtyPregnancyPediatricsbusiness.industryImmunologyPopulationCell BiologyHematologyAbortionmedicine.diseaseBiochemistryDasatinibGestational diabetesImatinib mesylateNilotinibmedicinebusinesseducationBreast feedingmedicine.drugBlood
researchProduct

Calidad de la atención al paciente oncológico: Tiempos asistenciales recomendables entre sospecha clínica y definición del plan terapéutico en cáncer…

2012

Fundamento. Determinar tiempos recomendables para el tratamiento desde la sospecha clínica fundada en los procesos asistenciales de cáncer de mama y colorrectal considerando factibilidad y situación personal del paciente. Método. Estudio cualitativo de búsqueda de consenso entre profesionales. Primero, se revisaron mediante 4 sesiones grupales (N=19), los procesos asistenciales de cáncer de mama y cáncer colorrectal y se fijaron los tiempos deseables de ambos procesos. Segundo, mediante una modificación de la técnica Delphi (N=49), se validó la propuesta de tiempos de atención recomendables para cada proceso asistencial. Resultados. La tasa de respuesta en el estudio Delphi fue del 69% en e…

Gynecologymedicine.medical_specialtyCare processInvasive carcinomacalidad asistencialbusiness.industryColorectal cancercáncer colorrectalRectumCancerGeneral MedicineSentinel nodemedicine.diseasecáncer de mamaSurgerymedicine.anatomical_structureBreast cancerTreatment planmedicineprotocolos tratamiento cáncerbusinessAnales del Sistema Sanitario de Navarra
researchProduct

In breast cancer, are treatments and survival the same whatever a patient's age? A population-based study over the period 1998-2009

2014

Aim The present study aimed to describe treatments, relative survival and prognostic factors in breast cancer patients according to age. Methods All women with primary invasive breast cancer, diagnosed from 1998 to 2009 in the department of Cote d'Or, were retrospectively selected. Variations in treatments administered according to age ( 74 years) and period were assessed using Cochran–Armitage trend tests and χ2-tests, respectively. Prognostic factors according to age were estimated using a generalized linear model with a Poisson error structure. Results Overall, 4305 women were included. The oldest women (aged >74 years) were more likely than the youngest women to have comorbidities, adva…

Gynecologymedicine.medical_specialtyRelative survivalbusiness.industryTumor biologymedicine.medical_treatmentmedicine.diseasePopulation based studyBreast cancerInternal medicineBreast-conserving surgeryAdjuvant therapyMedicineHormone therapybusinessHormoneGeriatrics & Gerontology International
researchProduct

Multicentre study of gestrinone in cyclical breast pain FRIEDOLF PETERS

1992

Although the aetiology of cyclical mastalgia is poorly understood, the consistent finding of an increased prolactin stimulation response probably due to oestrogen dominance has led to the use of treatment with prolactin-lowering drugs and antioestrogens. The efficacy and safety in cyclical mastalgia of gestrinone, which has androgenic, anti-oestrogenic, and antiprogestagenic properties, were investigated in a multicentre study. In a double-blind randomisation procedure, 72 patients were allocated placebo and 73 treatment with gestrinone (2.5 mg twice a week) for 3 months. The patients recorded the severity of breast pain on a visual analogue scale before and during treatment and scored othe…

Gynecologymedicine.medical_specialtybusiness.industryVisual analogue scaleBreast painGeneral MedicineGestrinonePlaceboGastroenterologyProlactinlaw.inventionRandomized controlled triallawInternal medicineSeverity of illnessmedicinemedicine.symptombusinessMastodyniamedicine.drugThe Lancet
researchProduct

BIOLOGICAL EFFECTS OF JAHA, A NEW HISTONE DEACETYLASE INHIBITOR, ON CANCER CELLS FROM HUMAN BREAST EPITHELIUM

The histone deacetylase inhibitors (HDACis) are a class of chemically heterogeneous anticancer agents of which suberoylanilide hydroxamic acid (SAHA) is a prototypical member. SAHA derivatives may be obtained by the three-dimensional manipulation of the SAHA aryl cap, such as the incorporation of a ferrocene unit like that present in Jay Amin hydroxamic acid (JAHA) and homo-JAHA (Spencer et al., 2011). These metal-based SAHA analogues have been tested for their cytotoxic activity toward triple-negative MDA-MB231 breast cancer cells. The results obtained indicate that of the two compounds tested, only JAHA was prominently active on breast cancer cells with an IC50 of 8.45 μM at 72 h of treat…

HDACi JAHA breast cancer MDA-MB231 cellsSettore BIO/06 - Anatomia Comparata E Citologia
researchProduct

Proteomic analysis of Herceptin-resistance breast cancer cells

2009

HER-2 breast
researchProduct

Fulvestrant and trastuzumab in patients with luminal HER2-positive advanced breast cancer (ABC): an Italian real-world experience (HERMIONE 9)

2021

Purpose: The most appropriate therapy for HR + /HER2-positive (HER2 +) advanced breast cancer (ABC) is a matter of debate. Co-targeting of both receptors represents an attractive strategy to overcome the cross-talk between them. Methods: The HERMIONE 9 is an observational retrospective multicentric study which aimed to describe the clinical outcome of patients with HR + /HER2 + ABC who received the combination of Fulvestrant (F) and Trastuzumab (T) as part of their routine treatment at 10 Italian Institutions. Results: Eighty-seven patients were included. Median age was 63 (range, 35–87) years. The median number of previous treatments was 3 (range, 0–10) and F and T were administered as ≥ 3…

HER2 positiveOncologyCancer Researchmedicine.medical_specialtySettore MED/06 - Oncologia MedicaReceptor ErbB-2Advanced breastBreast NeoplasmsBreast cancerMaintenance therapyTrastuzumabInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansFulvestrantRetrospective StudiesHormone receptor positiveFulvestrantbusiness.industryCancerMiddle AgedTrastuzumabmedicine.diseaseItalyOncologyCohortAdvanced breast cancerFemalePertuzumabbusinessmedicine.drugBreast Cancer Research and Treatment
researchProduct

Precision medicine in breast cancer: reality or utopia?

2017

International audience; Many cancers, including breast cancer, have demonstrated prognosis and support advantages thanks to the discovery of targeted therapies. The advent of these new approaches marked the rise of precision medicine, which leads to improve the diagnosis, prognosis and treatment of cancer. Precision medicine takes into account the molecular and biological specificities of the patient and their tumors that will influence the treatment determined by physicians. This new era of medicine is accessible through molecular genetics platforms, the development of high-speed sequencers and means of analysis of these data. Despite the spectacular results in the treatment of cancers inc…

HER2+0301 basic medicineTumor heterogeneitymedicine.medical_specialtyPathologyMolecular subtypeslcsh:MedicineBreast NeoplasmsReviewCancer VaccinesTumor heterogeneityGeneral Biochemistry Genetics and Molecular BiologyGenetic Heterogeneity03 medical and health sciencesBreast cancer0302 clinical medicineBreast cancer[ SDV.MHEP ] Life Sciences [q-bio]/Human health and pathologyHumansChemotherapyMedicineMedical physicsTriple negativebusiness.industrylcsh:RPrecision medicineCancerGeneral MedicinePrecision medicinemedicine.disease3. Good health030104 developmental biology030220 oncology & carcinogenesisNeoplastic Stem CellsTriple-negativeFemaleImmunotherapyPhase III clinical trialsbusiness[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologyJournal of Translational Medicine
researchProduct

Human milk is not “merely nutritious”: How its bioactive role can influence child health

2021

Maternal milk represents the best food for the newborn, providing specific physiologic advantages over the other sources of nutrition. It also contains many hundreds to thousands of bioactive molecules that protect against infection (i.e. IgA), inflammation (i.e. 5-methylthioadenosine) and contribute to eliciting strong immune responses in breastfed children (i.e. allergens or viral antigens). Quality and quantity of breast milk components may influence the development of infant body composition in the first years of life; in particular, it has been shown that a different composition of human oligosaccharides (HMOs) in overweight/obese women’s human milk can be correlated with her offspring…

HMOMicrobiotaBreastfeedingBioactive compound
researchProduct

DIFFERENTIAL INFLUENCE OF HYPOXIA ON GENE EXPRESSION OF TUMORAL AND NON TUMORAL MAMMARY CELLS

2015

Cancer metastasis is the result of a series of deregulated biological phenomena, including alterations of cell-cell and cell-matrix interactions and of other microenvironmental conditions such as the oxygen tissue supply. Hypoxia is a well-known driver of aggressive cancer phenotypes, indeed tumors with poor prognosis have higher proportions of anoxic and hypoxic areas1. The consequences of tumour hypoxia can be local or even systemic towards distant organs, and it can evoke diversified responses: whereas low oxygen concentration in tissue environments. (pO2 <7 mmHg) exerts anti-proliferative effects and promotes differentiation, apoptosis and/or necrosis on normal cells, the tumoral cells …

HYPOXIA BREAST CANCER
researchProduct